History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio.

The $210 case is primarily a compounding-and-multiple assumption, not a near-term catalyst: it requires adjusted EPS to compound at 8% while the terminal multiple stays near today’s forward multiple. Calling that conservative is debatable because the prior decade’s growth included sizeable acquisitions; organic growth, integration, and capital allocation are the key variables, not the historical CAGR alone. The Exact Sciences deal adds a specific execution test: potential portfolio and commercial synergies could strengthen Abbott’s diagnostics offering, but all-cash funding raises the importance of interest expense, debt trajectory, and whether acquired earnings translate into per-share growth. Scale competition could intensify for other diagnostics providers, though the article provides no evidence yet of material customer switching or share loss.

Over the next few months, focus on guidance and management’s first measurable integration and financing updates; over 6–18 months, judge whether Exact Sciences contributes to organic growth and cash generation without constraining dividends or other investment. The contrarian point is that a long runway and dividend record do not make the equity low-risk: even with EPS growth, multiple compression or weaker-than-expected acquisition returns can materially reduce the price outcome. The thesis weakens if Abbott cuts its outlook, acquisition-related costs or interest burden undermine per-share growth, or debt fails to trend toward management’s stated objectives. No immediate catalyst in the article justifies treating the decade-long scenario as a short-term valuation signal.